Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)

Melanoma Management

Jonathan S Zager¹  Matthew C Perez¹  Thomas Amatruda²  Robert Conry³  Charlotte Ariyan⁴  Anupam Desai⁵  John M Kirkwood⁶  David Cohan⁷  Sheryl Treichel⁷  Leon Raskin⁷ 

[1] 1Moffitt Cancer Center, Tampa, FL 33612, USA;2Minnesota Oncology, Fridley, MN 55432, USA;3The University of Alabama at Birmingham, Birmingham, AL 35294, USA;4Memorial Sloan Kettering Cancer Center, NY 10065, USA;5Beth Israel Deaconess Medical Center, Boston, MA 02215, USA;6UPMC Hillman Center, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA;7Amgen Inc., Thousand Oaks, CA 91320, USA;

关键词: combination therapy;    immunotherapy;    melanoma;    metastatic melanoma;    oncolytic virus;    real-world evidence;   

DOI  :  10.2217/mmt-2019-0012

来源: DOAJ

【 摘 要 】

Aim: Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice. Materials & methods: A chart review was conducted at seven centers, with 78 patients screened and 76 eligible. Results: Patients began treatment with T-VEC between October 2015 and December 2016. Median follow-up was 9.4 months. Twenty percent of patients (n = 15) completed T-VEC treatment with no remaining injectable lesions or pathologic complete response. Flu-like symptoms were the most commonly reported adverse events (n = 8; 10.5%), followed by lesion ulceration (n = 4; 5.3%). No herpetic lesions or infections were reported. Conclusion: T-VEC was well tolerated and showed clinical utility.

【 授权许可】

Unknown